Oncology Nursing News®

Breast Cancer

Neoadjuvant Durvalumab Is Promising for TNBC Treatment

Neoadjuvant Durvalumab Is Promising for TNBC Treatment

BY JASON M. BRODERICK

Palbociclib Shows OS Benefit in Frontline HR+/HER2- Breast Cancer

Palbociclib Shows OS Benefit in Frontline HR+/HER2- Breast Cancer

BY JASON M. BRODERICK

T-DXd Could Be New Standard of Care for Breast Cancer Subset

T-DXd Could Be New Standard of Care for Breast Cancer Subset

BY KRISTIE L. KAHL

FDA Approves Generic Everolimus Tablets

FDA Approves Generic Everolimus Tablets

BY KRISTI ROSA

Overcoming AI Resistance in ESR1-Mutant Breast Cancer

Overcoming AI Resistance in ESR1-Mutant Breast Cancer

BY CAROLINE SEYMOUR

Biosimilars Poised to Help Patients Handle Rising Drug Costs

Biosimilars Poised to Help Patients Handle Rising Drug Costs

BY CAROLINE SEYMOUR

Utilizing Actionable Classifications in TNBC

Utilizing Actionable Classifications in TNBC

BY ADITYA BARDIA, MD, MPH

OS Benefit is Shown in CDK4/6 Inhibitors for Metastatic HR+ Breast Cancer

OS Benefit is Shown in CDK4/6 Inhibitors for Metastatic HR+ Breast Cancer

BY ELLIE LEICK

African American Women Aren't Receiving the Benefits of Breast Cancer Awareness

African American Women Aren't Receiving the Benefits of Breast Cancer Awareness

BY KAREN HARRIS, MSN, RN

KATE2 Study Misses Endpoint, Appears Promising for HER2+, PD-L1-Expressing Breast Tumors

KATE2 Study Misses Endpoint, Appears Promising for HER2+, PD-L1-Expressing Breast Tumors

BY CONOR KILLMURRAY

External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc

OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives

About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.